Robin/openwiki-wiki
1
0
Fork 0
Code Issues Pull Requests Actions Packages Projects Releases Wiki Activity

chore: daily update 2026-07-31

Browse Source
This commit is contained in:
OpenWiki Bot
2026-07-31 02:21:11 +08:00
parent 5fbc0077b3
commit 79ef9939c7
6 changed files with 82 additions and 10 deletions
Download Patch File Download Diff File Expand all files Collapse all files
commitments.md
+14
View File
@@ -39,6 +39,20 @@ Concrete work tasks, follow-ups, approvals, and scheduled items extracted from G
- Status: open
- Notes: Material new development in the China regulatory lane — sits **on top of** the existing `china-cde-cell-gene-therapy-rules-2026` and `china-order-no-818-clinical-translation` items, not replacing them. Two positive signals (Merck–Bio-Techne acquisition; CARsgen satri-cel solid-tumor CAR-T approval) show the China CGT manufacturing environment is consolidating around advanced therapeutics. One negative signal (gene-editing trial death + published regulatory backlash) could foreshadow stricter CDE / NMPA / hospital-level oversight and tighter qualification criteria for "qualified hospitals" under Order No. 818. Together these affect: (a) qualification timelines for the CellShot-TriArm and ClinoReactor-class deals Robin has in flight, (b) which "qualified hospitals" remain eligible to host first-in-human studies, (c) whether CelVivo / 3Brain / Cellink vendor positioning for Chinese pharma R&D / CDMO accounts needs to change tone (e.g. emphasize safety documentation, IRB-grade workflows). Pull NMPA / hospital-IRB statements on the gene-editing trial case before next Chinese customer conversation.
### 3brain-coreplate-2026-conference-positioning: verify current CorePlate campaign and retrieve application material on next 3Brain check
- Owner: me
- Source: web-search — 3Brain official website plus 3Brain organization material captured through LinkedIn in Tavily pull 7 (2026-07-30); the dated result is 2026-07-25 and names ISSCR 2026 booth 412, while the company page also names ELRIG Drug Discovery booth 4
- Due: unscheduled
- Status: open
- Notes: First credible direct 3Brain evidence after five Tavily pulls dominated by an unrelated EEG-paper mis-attribution. Vendor material positions CorePlate-enabled HD-MEA for high-resolution, scalable functional readouts from iPSC neuronal/cardiac models, brain organoids, assembloids, and 3D spheroids. Confirm which conference posts are current, obtain the named posters/application notes, and map them to Chinese neural-organoid and pharma-screening prospects. This pull does not establish CorePlate 1W/6W load force or Sample Holder Set details.
### celvivo-clinostar-2-nams-demo-2026: verify product naming and campaign provenance on next CelVivo check
- Owner: me
- Source: web-search — Instagram snippets surfaced in Tavily pull 7 (2026-07-30): ClinoStar webinar copy (`DbaUZjIjMgK`), NexUs Locus on-site demo copy dated 2026-07-24 (`DbKYC4NBtrN`), and ClinoStar 2 NAMs positioning (`DbSl7nkoFjK`)
- Due: unscheduled
- Status: open
- Notes: Watchlist lead, not a confirmed launch or customer win. Verify that the posts come from CelVivo or an authorized distributor, whether `ClinoStar 2` is current official product naming, and whether the NexUs Locus live demo produced reusable data or contacts. The result set does not support Tavily's “installed base” language; one malformed duplicate URL was discarded.
<!--
Structure for new entries: